On October 20, 2026, Cantor Fitzgerald started coverage of Ensysce Biosciences Inc (ENSC) at Overweight.
The past 90 days include one active firm, with one rating the stock bullish. The consensus price targets from four analysts as of October 30, 2026, have a mean of $5.23, a median of $5.23 and a range of $2.02 to $8.66.
The Q4 FY2026 consensus calls for -$0.10 in EPS on $1.22 million in revenue. The next earnings date is November 12, 2026.
